DPP-4 Inhibitor-Related Pancreatitis: Rare but Real!
- DeVries, Hans J.
- Rosenstock, Julio
1Department of Endocrinology, Academic Medical Center at the University of Amsterdam, Amsterdam, the Netherlands
2Dallas Diabetes Research Center, Dallas, TX
Corresponding author: J. Hans DeVries, e-mail:[email protected].
See accompanying articles, pp. 164 and 284.
Acknowledgments. The authors would like to thank Erik Rauws, MD, Academic Medical Center, Amsterdam, and Gerald Isbell, MD, Medical City Dallas Hospital, Dallas, TX, gastroenterologists, for their blinded assessment of possible pancreatitis cases adjudicated negatively in TECOS and Lizzy Brewster, MD, Academic Medical Center, Amsterdam, for statistical advice.
Duality of Interest. J.H.D. or his affiliated institutions have received honoraria from manufacturers of incretin-based therapies: Eli Lilly, Merck, Novo Nordisk, and Sanofi, for lecture invitations and consulting. J.R. has served on scientific advisory boards and received honoraria or consulting fees from manufacturers of incretin-based therapies: Eli Lilly, Novo Nordisk, Sanofi, Merck, Daiichi Sankyo, Boehringer Ingelheim, AstraZeneca, and Intarcia. J.R. has received grants or research support from manufacturers of incretin-based therapies: Merck, Sanofi, Novo Nordisk, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Takeda, AstraZeneca, Hanmi, Boehringer Ingelheim, and Intarcia. No other potential conflicts of interest relevant to this article were reported.
